Previous 10 | Next 10 |
2023-03-27 10:47:00 ET Gainers: Pyxis Oncology ( PYXS ) +25% . Delcath Systems DCTH +23% . Jounce Therapeutics ( JNCE ) +23% . Alimera Sciences ( ALIM ) +22% . Coeptis Therapeutics ( COEP ) +21% . Losers: Unity Biotechnology ...
Repurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000 Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share price on March 24, 202...
ATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will repo...
ATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces th...
Alimera Sciences ( NASDAQ: ALIM ) said its distribution partner Horus Pharma through its Swiss affiliate Horus Pharma Suisse filed a marketing authorization application (MAA) in Switzerland for Iluvien to treat diabetic macular edema (DME). The Swiss application for consist...
ATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that its...
ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced t...
ATLANTA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announces f...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although it’s not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising , investors need to start preparing for the worst. Of c...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-25 11:30:02 ET Alliance Global Partners analyst issues NEUTRAL recommendation for ALIM on June 25, 2024 10:23AM ET. The previous analyst recommendation was Buy. ALIM was trading at $5.53 at issue of the analyst recommendation. The overall analyst consensus : HOLD...
2024-06-25 07:00:05 ET Yi Chen from H.C. Wainwright issued a price target of $6.00 for ALIM on 2024-06-25 06:08:00. The adjusted price target was set to $6.00. At the time of the announcement, ALIM was trading at $5.54. The overall price target consensus is at $7.25 with...